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Background: Hyopkalemia is a listed toxicity in the capecitabine (Xeloda®; Roche, Nutley, NJ)
package insert. However, the incidence and severity of this toxicity is not known.
Methods: We performed a retrospective evaluation of hypokalemia in 77 patients, who received
capecitabine for gastrointestinal malignancies between April 2002 and November 2004.
Hypokalemia was defined as K+ level <3.2 mEq/L. Patients with documented ≥grade 2 vomiting
or diarrhea, diuretics, hypomagnesemia, hypokalemia, renal insufficiency, endocrine dysfunction
(thyroid, adrenal, diabetic) were excluded. Hypokalemic patients were graded as: mild (grade 1:
3.0–3.2 mEq/L), moderate (grade 3: 2.5–2.9 mEq/L) and severe (grade 4: <2.5 mEq/L). We also
reviewed the literature.
Results: Fifty-four patients met the above criteria. The most common cause of exclusion was ≥
grade 2 diarrhea (23 patients; 30%). Overall, hypokalemia was encountered in 11 patients (20.4%).
Among hypokalemic patients, 8 patients (73%) presented with mild/grade 1 hypokalemia (3.0–
3.2 mEq/L), 2 patients (18.18%) with moderate/grade 3 hypokalemia (2.5–2.9 mEq/L) and
1 patient (9.09%) with severe/grade 4 hypokalemia (<2.5 mEq/L) 8 (73%). Dose of capecitabine
ranged between 1000–2000 mg/m2. Hypokalemia occurred after an average of 83.7 days of
capecitabine administration. No cardiac or neuromuscular complications were noticed. Replacement
of K+ was required in 6 patients (2 intravenous and 4 oral), while 2 patients (3.7%) required oral
supplements >4 weeks. No patient had to stop capecitabine due to hypokalemia. One patient had
persistent hypokalemia even after stopping capecitabine. Normalization of K+ levels was achieved
in 91% of patients. Four patients were on K+ sparing diuretics for ascites and never presented with
hypokalemia. Mean urine K+ was 28 mEq/L. Only 5.5% patients had ≥grade 3 hypokalemia in our
study compared with 2% and 14% in two other studies.
Conclusions: Although diarrhea being the most common cause of hypokalemia in patients on
capecitabine, we postulate that hypokalemia may also be related to the effect of capecitabine on
renal tubules suggested by the urine K+ in some patients. Due to potential complications, hypokalemia
in patients on capecitabine deserves special diagnostic and therapeutic attention.
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Introduction
Capecitabine (Xeloda
®; Roche, Nutley, NJ) is a tumor-activated antineoplastic agent
(antimetabolite) belonging to the novel fluoropyrimidine carbamate class (FDA 2001).
Capecitabine is currently indicated for the first-line treatment of patients with metastatic
colorectal carcinoma when treatment with fluoropyrimidine therapy alone is preferred
(Hoff et al 2001; Van Cutsem et al 2001). It is also indicated in combination with
docetaxel for the treatment of patients with metastatic breast cancer after failure of
prior anthracycline containing chemotherapy (O’Shaugnessy et al 2002) and as
monotherapy for the treatment of patients with metastatic breast cancer resistant to
both paclitaxel and an anthracycline-containing chemotherapy or resistant to
paclitaxel, but with contraindications to anthracyline therapy (Blum et al 1999). The
studies in these cancer populations have shown evidence that capecitabine provides
an effective alternative to current standard intravenous chemotherapy and in some
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instances superior efficacy in treatment of metastatic
colorectal and breast cancer (Twelves 2002). Capecitabine
allows patients to avoid the placement of long-term
intravenous access which provides two major benefits: fewer
complications associated with intravenous catheters and more
freedom for the patient during the treatment process.
Capecitabine is currently being evaluated for use in
combination with radiotherapy and other chemotherapeutic
agents such as oxaliplatin, irinotecan, and many others.
The most common side effects of capecitabine include
diarrhea, nausea, vomiting, stomatitis, abdominal pain, hand-
and-foot syndrome, and fatigue. These side effects are similar
to what one would expect in using fluoropyrimidines. However,
when compared with intravenous bolus infusion of 5-FU/LV
(Mayo Regimen) in these phase III studies, the incidence of
nausea, diarrhea, and alopecia were significantly lower in the
patients receiving capecitabine (Twelves 2002). The patients
receiving capecitabine also had lower incidences of grade 3
to 4 stomatitis and neutropenia resulting in less frequent
hospitalizations. Incidences of fatigue and vomiting were
similar in both arms of the study. Capecitabine was associated
with more frequent occurrences of hand-foot syndrome, but
this can be successfully managed by dose reduction and
prevention. The most significant laboratory abnormality
found in the capecitabine arm compared with 5-FU arm was
elevation of total bilirubin. Elevated total bilirubin was found
in 21% of patients receiving capecitabine versus only 2% of
patients receiving 5-FU/Leucovorin (Twelves 2002).
Less frequent but serious complications of capecitabine
include cardiotoxicity, and neurotoxicity (Saif et al 2003,
2004). Hypokalemia has not been reported frequently with
capecitabine. We encountered three patients who developed
hypokalemia in the absence of diarrhea, vomiting, or other
etiologies. This prompted us to perform a retrospective study
to determine incidence, risk factors, complications, and
management of hypokalemia in patients receiving
capecitabine. To systematically estimate the frequency of this
complication of capecitabine
 therapy, we obtained a waiver
of authorization
 from the institutional review board (IRB) of
University of Alabama at Birmingham (UAB) to review the
laboratory and pharmacy
 profiles for all gastrointestinal (GI)
malignancy patients treated with
 capecitabine.
Patients and methods
Retrospective review of all patients with GI malignancies
who were treated with capecitabine alone or capecitabine-
based regimen by one of the oncologists from April 2002
and November 2004 at the UAB was conducted after approval
from the IRB. A total of 77 patients were identified with a
final diagnosis of cancer arising in the pancreas, colon,
rectum, liver, and stomach. Neither clinical trials nor standard
practice
 guidelines mandated routine monitoring of
potassium levels.
Exclusion criteria included presence of documented  ≥ grade 2
(NCI-CTC 2.0) vomiting or diarrhea, concomitant use of diuretics
or antibiotics (eg, penicillin, gentamicin, amphotericin),
hypomagnesemia, history of hypokalemia prior to capecitabine
administration, renal insufficiency, thyroid (hypothyroidism)
or adrenal dysfunction (Addison’s) and diabetic nephropathy.
Out of 77 patients, 54 were eligible.
The data including age, sex, race, initial weight, final
diagnosis, dose and date of capecitabine administration,
concurrent diuretics, radiation (XRT) or other chemotheraputic
agents, diabetes mellitus, hypothyroidism, and renal
dysfunction were recorded. We also collected the laboratory
results on serum creatinine, potassium, magnesium, and urine
potassium in these patients. Most of these patients had three-
weekly laboratory data collection, while after noticing
hypokalemia, serum electrolytes were followed weekly till
resolution of the abnormality. The urine electrolytes, in
particular urine K
+ were available only in patients who were
worked up for hypokalemia. Patients charts were reviewed to
evaluate for any cardiac (symptoms or electrocardiogram
[EKG] changes) or neuromuscular complications due to
hypokalemia. Also information about potassium replacement
was collected up to a month after stopping capecitabine.
Statistical analysis
Hypokalemia was defined as K
+ level <3.2 mEq/L. Patients
were classified into 3 groups based on K
+ levels: (1) mild/
grade 1 (3.0–3.2 mEq/L), (2) moderate/grade 3 (2.5–2.9 mEq/L)
and, (3) severe/grade 4 (<2.5 mEq/L). Baseline serum and
urine values (if available) were compared with values
obtained after capecitabine administration. For subjects with
more than one urine sample within an interval, the mean of
the individual samples was used. Correlation between serum
creatinine and potassium was analysed. All data were recorded
in Microsoft Excel 98 (Microsoft Corporation; Seattle, WA);
all statistical analysis was performed using SAS
 (version 8.2;
SAS Institute; Cary, NC).
Results
Among 77 patients identified, 54 patients met the eligibility
criteria as described above. They were 30 male and 24 femaleTherapeutics and Clinical Risk Management 2007:3(1) 179
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patients with median age of 60 years (range: 32–89).
The final diagnoses included: pancreatic cancer (31), colon
cancer (19), hepatocellular carcinoma (3), and gastric
cancer (1) (Table 1). The most common reason for exclusion
was diarrhea ≥grade 2 (23 patients; 30%). Twenty patients
received capecitabine monotherapy (37%): 5 patients
received capecitabine alone and 15 patients received
capecitabine with concomitant XRT followed by capecitabine
monotherapy (all pancreatic cancer patients who received
this regimen as a part of a clinical trial); and 34 patients in
combination with other chemotherapeutic agents (63%).
These agents included oxaliplatin and irinotecan, both not
known to cause hypokalemia. The dose of capecitabine
ranged between 1000–2000 mg/m
2. No correlation between
the dose of capecitabine and hypokalemia was observed in
these patients.
Among 54 patients who received capecitabine and met
our criteria, 11 patients (20.4%) had hypokalemia. Of those,
8 patients (73%) presented with mild/grade 1 hypokalemia
(3.0–3.2 mEq/L), 2 patients (18.18%) with moderate/grade 3
hypokalemia (2.5–2.9 mEq/L) and 1 patient (9.09%) with
severe/grade 4 hypokalemia (<2.5 mEq/L) (Table 2). No
patient developed any cardiac (EKG) or neuromuscular
complications due to hypokalemia. Diagnosis of
hypokalemia occurred after an average of 83.7 days of
capecitabine administration. Six patients (11%) required
replacement of K
+: 2 patients received intravenous K
+; 4
patients were administered oral K
+). Continued administration
of oral supplements of K
+ > 4 weeks was required in 2 patients
(3.7%). One patient (1.8%) had persistent hypokalemia even
after stopping capecitabine. None of our patients had to stop
capecitabine due to hypokalemia. Normalization of
potassium levels was achieved in 91% of patients. Four
patients (7.4%) were on K
+ sparing diuretics (spironolactone)
for ascites and never presented with hypokalemia.
No correlation in serum creatinine and hypokalemia was
noticed. However, decrease in serum K
+ was proportional to the
amount of urine K
+ (Table 2). Mean urine K
+ was 28 mEq/L
(range: 21–51 mEq/L), suggesting renal loss of potassium in
these patients.
Discussion
No previous case reports relating an association between
capecitabine use and the occurrence of hypokalemia are found
in the literature. The capecitabine package insert does list
that hypokalemia is a potential toxicity under capecitabine
monotherapy in breast and colorectal cancer (Roche
Pharmaceuticals 2001), but the real incidence or the severity
of this side effect is not known. We found hypokalemia in
>20% of patients on capecitabine without any obvious
etiology, including severe diarrhea or vomiting or the use of
loop diuretics. Approximately 5.5% patients had ≥grade 3
hypokalemia. The incidence of hypokalemia might be higher
as few patients (7.4%) were on K
+ sparing diuretics. No
correlation between hypokalemia and dosage of capecitabine
was observed. However, there was an apparent relation
between the serum K
+ and urine K
+ levels. Due to the potential
complications, hypokalemia in patients on capecitabine
deserves special diagnostic and therapeutic attentions.
Further analysis to characterize the mechanism is needed.
The most common reason for exclusion was diarrhea
≥grade 2 (23 patients; 30%). This finding is akin to the
observed incidence of diarrhea in major studies which
evaluated capecitabine such as those performed by Van
Custem et al (2001) and Hoff et al (2001). However, we did
not find any information about hypokalemia in both studies.
In the study done by Hoff et al (2001), 8 (2.7%) patients
required in-patient re-hydration. In the study done by Van
Custem et al (2001), 5 (1.7%) patients required in-patient re-
hydration. We reviewed studies as well as other major trials
on the pub med. In the study by Cassidy  and colleagues
Table 1 Demographic data of patients with gastrointestinal
malignancies on capecitabine
Total = 5 4*
Gender = male: female (54) = 30:24
Age: Median (range) 60 years (32–89)








Capecitabine + XRT 15
Capecitabine + other chemotherapic agent(s) 34
Average days since Xeloda at time of
hypokalemia 84 days
Grades of hypokalemia
Mild/Grade 1 hypokalemia (3.0–3.2 mEq/L) 8
Moderate/Grade 3 hypokalemia (2.5–2.9 mEq/L) 2
Severe/Grade 4 hypokalemia (<2.5 mEq/L) 1
Mean urine potassium 28 mEq/L
(range: 21–51)
Note: *54 out of 77 patients met the criteria.Therapeutics and Clinical Risk Management 2007:3(1) 180
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(2002) comparing capecitabine versus 5-FU in metastatic
colorectal cancer mentioned the incidence of laboratory
abnormalities, including liver
 enzymes and blood count, but
no data is available regarding potassium in the published
paper. In a phase II study done by Jatoi and colleagues (2006)
evaluating oxaliplatin and capecitabine in patients with
metastatic adenocarcinoma of the esophagus, gastroesophageal
junction, and gastric cardia, 6 (out of 43) patients developed
≥ grade 3 hypokalemia (14%). In our study, of the 11 patients
who developed hypokalemia: 2 were on oxaliplatin with
capecitabine; 1 was on irinotecan with capecitabine; and the
remaining 8 were on capecitabine monotherapy. Both these
agents (oxaliplatin, irinotecan) are not known to cause
hypokalemia. However, we suggest that the interaction of all
these combinations need to be looked at as confounding
factors.
We suggest that, like several other important oncology
drugs such as cisplatin, which is known to be associated with
excessive loss of magnesium and potassium in the urine
(Rodriguez et al 1989), capecitabine may also impair
potassium reabsorption
 in the kidney and may cause
clinically significant hypokalemia. We suggest that similar
cases of hypokalemia associated with capecitabine should
be reported if observed. Spot urine potassium might be a
helpful diagnostic test in detection of the source of potassium
loss in these patients. However, a 24-hour collection of urine
for potassium would yield better information.
The pitfalls of retrospective study are well known, such
as lack of complete information about the toxicities and the
absence of urine K
+ in all the hypokalemic and normokalemic
patients, but some conclusions may be drawn from this study.
Our study showed that late onset hypokalemia was
encountered in >20% of patients on capecitabine. Most of
the patients (73%) presented with grade 1 hypokalemia, and
18.18% with grade 3 hypokalemia and 9% with grade 4
hypokalemia. It is reassuring that no significant clinical
problems were found in the patients in this study. We believe
that our findings on hypokalemia in this study are intriguing
and suggest the need of more research on this topic.
Management of hypokalemia in patients on capecitabine
deserves special attention due to the potential complications.
This issue is also significant in patients who are already on
diuretics. Further analysis will be required to characterize
the mechanism for the apparent renal potassium wasting in
these patients.
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Table 2 Correlation of hypokalemia with other factors
Total = 11 Mild/Grade 1 Moderate/Grade 3 Severe/Grade 4
hypokalemia (N = 8) hypokalemia (N = 2) hypokalemia (N = 1)
Serum creatinine (mg/dl) mean (range) 0.97 (0.4–1.1) 0.85 (0.6–1.1) 0.6
Urine potassium (mEq/L) mean (range) 21 (18–28) 36 (31–36) 51*
Level of Mg at low potassium (mg/dl) 1.65 1.5 2.0
Capecitabine dose  (1000 mg/m2)2 1 0
Capecitabine dose (2000 mg/m
2)6 1 1
Note: *Available in only one patient.